EGFR and non-small cell lung carcinoma: In detail, in the phase III MARIPOSA trial, including patients with untreated EGFR-mutated NSCLC, the risk of VTE at a median follow-up of 22 months was 37% in the amivantamab–lazertinib group (n = 429) and 9% in the osimertinib group (n = 429) [3].